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Abstract
The proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch
a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical
study designs and analytical methods undermines the current ability to achieve this. The proposed
World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical
database from which standardised estimates of antimalarial efficacy can be derived and monitored
over time from diverse geographical and endemic regions. The emphasis of this initiative is on five
key variables which define the therapeutic response. Ensuring that these data are collected at the
individual patient level in a consistent format will facilitate better data management and analytical
practices, and ensure that clinical data can be readily collated and made amenable for pooled
analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends
in drug efficacy. This will guide not only appropriate interventions to deal with established
multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug
resistant plasmodia first emerge. A comprehensive global database incorporating the key
determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will
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bring together relevant data on host, drug and parasite factors that are fundamental contributors
to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial
drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not
prevented, at least delayed.
Background
The emergence and spread of antimalarial drug resistance
is one of the most important factors undermining malaria
control programmes in most of the malaria endemic
world. [1]. Following World Health Organization (WHO)
recommendations, more than 60 countries have now
adopted artemisinin-based combination therapies (ACT).
Changing national policy in resource-poor settings has
huge financial and practical implications and the debate
continues as to which are the most suitable combinations
and how these new treatments should be deployed and
funded. In this context, it becomes of paramount impor-
tance to policy makers, funding bodies and researchers
alike, to document the clinical efficacy of older drugs now
being combined with artemisinins and to monitor the
continued efficacy of newly deployed antimalarial regi-
mens.
The number of clinical trials being conducted has risen
dramatically over the last decade. This is primarily in
response to an increasing appreciation of the major
impact that antimalarial drug resistance has had on the
health of tropical communities, the perceived need for the
rational deployment of new regimens based on empirical
evidence and a significant increase in the funding for these
critical endeavours. Numerous groups have now gener-
ated a wealth of knowledge on different treatment regi-
mens in different sites over a prolonged period of time.
Unfortunately many studies remain unpublished. While
each trial may have been designed with an immediate
applicability for local policy makers or to test a specific
hypothesis, an opportunity exists to extract information
of global relevance.
Combining published and unpublished data from differ-
ent sites into a comprehensive global database will pro-
vide the ability to monitor geographical and temporal
trends in clinical efficacy to drugs that are being used as
well as new drugs that are being evaluated. Such informa-
tion will facilitate the early recognition of problems with
antimalarial efficacy as they first emerge in affected areas
and, perhaps more importantly, before they appear in
adjacent areas. Prompt recognition of the earliest signs of
compromised drug efficacy is particularly important now,
as highly effective ACTs are increasingly becoming the
first-line treatment in most of the world. A global data-
base for monitoring clinical efficacy of antimalarial drugs
linked to similar databases tracking in vitro, molecular and
pharmacokinetic information will directly inform deci-
sions about which drugs should be used in specific set-
The broad aims of the global efficacy database Figure 1
The broad aims of the global efficacy database.
x Collate data from studies conducted in different geographical locations 
x Monitor temporal trends in clinical and parasitological efficacy 
x Detect the emergence and spread of antimalarial drug resistance 
x Track geographical trends in antimalarial drug efficacy, after controlling for 
important confounding host and parasite factors 
x Develop appropriate resources, support and technologies to help researchers 
conduct, analyse and promptly report antimalarial efficacy studies 
x Provide a tool allowing the optimization of current antimalarial treatment 
regimens through a better understanding of the spread of resistance and how 
this is influenced by host, parasite and pharmacokinetic interactionsMalaria Journal 2007, 6:119 http://www.biomedcentral.com/1475-2875/6/119
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tings to assure adequate cure rates for afflicted
populations (Figure 1). Equally important, this network
will provide a comprehensive view of the evolution of
resistance that may lead to new strategies for deploying
effective antimalarial combinations in ways that will deter
the emergence and spread of resistance.
Rationale for an individual patient level database
The antimalarial drug response can be characterized
through a triad of in vivo, in vitro and molecular studies.
For clinicians and policy-makers the most informative
measure on which to base treatment practices is the in vivo
response of patients within a target population. However,
the therapeutic response must be interpreted as an inter-
action between the host, the parasite and the adminis-
tered drug (Figure 2). The cost and logistics of in vivo
clinical studies severely limit the availability of these data.
In vitro and molecular data provide additional informa-
tion on parasite susceptibility in the absence of the con-
founding environment of the host, but often their clinical
relevance is difficult to gauge.
Between 1966 and 2002, more than 435 antimalarial drug
trials involving over 80,000 patients were published [2].
There is also a large number of studies [3]. Furthermore,
there is frequently a delay of several years between the
completion of a study and its publication, often related to
difficulty in presenting and analysing the data. In order to
leverage this huge and evolving resource to provide stake-
holders with the current status of antimalarial efficacy, the
available data must be systematically gathered, collated,
analysed and presented in a timely fashion. The current
heterogeneity in analyzing and reporting such studies is a
major impediment to reaching this goal.
Systematic review provides one approach to combining
data but it lacks the power of large individual patient anal-
yses and is not amenable to standardizing analytical
methods or sub-group analyses. Meta-analyses of pub-
lished studies pool data from multiple studies, but these
studies tend to focus on specific treatment regimens and
differences between treatments in comparative studies
rather than providing standardized estimates of drug effi-
cacy across different studies. Aggregating data from pub-
lished reports can provide useful indicators of the global
situation of antimalarial resistance [3]. However in the
absence of individual patient level data, this approach is
limited by the diversity of study designs and analyses and
variations in the populations being studied.
An alternative approach is to gather individual patient
data from published and unpublished studies [4].
Although protocols for conducting antimalarial efficacy
trials have been standardized to some extent by the WHO,
the recommendations have been revised three times over
the last decade, thus limiting comparisons of historical
data. For example, the duration of follow-up is a key factor
that determines the derived estimates of drug efficacy.
Until recently, WHO recommended a 14-day period of
follow-up in areas of high transmission, although this
short follow-up period was also often used in intermedi-
ate and low transmission settings. When resistant isolates
first emerge in the parasite population, parasite recrudes-
cence tends to occur late (up to 63 days after the initial
treatment for drugs with long terminal elimination half-
lives). Studies with less than 28 days follow-up, therefore,
do not adequately assess the true cure rate and are unable
to detect early evidence of resistance [5]. By the time that
early treatment failures occur and recurrent infections are
Determinants of in vivo response to antimalarial therapy Figure 2
Determinants of in vivo response to antimalarial therapy.
The Host  The Parasite  The Drug 
Age
Immunity
Pregnancy
Nutrition
Adherence
Pharmacogenetics
Biomass
Polyclonality
Mixed Infections 
Sequestration
Synchrony
Resistance
Pharmacokinetic / pharmacodynamic profile 
Formulation
Tolerability profile 
Dosage and duration of treatment 
Drug quality Malaria Journal 2007, 6:119 http://www.biomedcentral.com/1475-2875/6/119
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observed before day 14, parasite resistance is already
firmly established [6]. Further confusion arises from the
distinction between the definitions of late clinical and
parasitological failure. Previous WHO protocols consid-
ered treatment failure in high transmission areas only if
recurrent parasitaemia was accompanied by fever. In low
transmission settings, where most people with recurrent
parasitaemia become symptomatic, studies generally
define failure as occurrence of any parasitaemia, irrespec-
tive of symptoms. These fundamental differences in defin-
ing the main study endpoints undermine comparison of
drug efficacy between low and high transmission sites and
severely compromise analysis of geographic trends in
antimalarial drug resistance. In 2001 the WHO protocol
was revised again to follow patients for at least 28 days [7],
defining failure as the recurrence of any recrudescent par-
asitaemia, even without symptoms. Although such
changes will help standardize estimates of efficacy, the
longer follow-up requires that the studies should be com-
plemented by molecular genotyping to distinguish recru-
descence (true treatment failure) from reinfection.
Currently there are no agreed guidelines on how this crit-
ical distinction should be made [8].
Despite these improvements in the most recent WHO pro-
tocol, variations in study design by individual investiga-
tors are likely to continue. In addition, differences in
study populations with respect to key determinants of
antimalarial response, such as patient age and parasite
density [9], will continue to make comparison of esti-
mates of treatment efficacy across different studies chal-
lenging.
Even with standardized study design and enrollment cri-
teria, derived estimates of efficacy presented in compara-
tive drug trials can vary significantly as a result of
differences in the statistical analysis [10]. To maintain a
conservative analytical approach, comparative drug stud-
ies are often constrained to per-protocol populations or
emphasis is placed on intention-to-treat analyses.
Although these methods maintain an internal validity,
they introduce important biases in the analysis when
combining patients who were followed for different peri-
ods. The duration of follow-up varies due to differing
study designs, patient adherence, and reinfection and
relapse rates, and together these variables can change the
evaluable population in the study by up to 50%. Efficacy
estimates have fluctuated by more than 10% when the
same study is evaluated by these different protocols [11].
Since the latest WHO guidelines state that a treatment reg-
imen should not be considered effective if the risk of
recrudescence exceeds 10%, variations in efficacy esti-
mates entirely attributable to statistical methodology can
have important implications on policy decisions.
A primary goal of a comprehensive global data base is to
allow antimalarial drug efficacy to be monitored and
compared between diverse sites and over time. To achieve
this, the clinical and parasitological data need to be ana-
lysed at an individual patient level. This approach allows
the attributable component of parasite resistance to be
established after minimizing the confounding of host and
drug-related factors. The additional advantage of this
approach is that when available in vitro, molecular and
pharmacokinetic data exist they can be linked at an indi-
vidual level, leading to a better understanding of how
these variables correlate with the therapeutic response.
The Challenge
There are two main challenges that must be addressed
before standardized efficacy estimates can be derived from
a global database. First, a simple, reliable and comprehen-
sive method to organize a core set of primary data from
different study sites and research groups must be estab-
lished. Second, an appropriate a priori analytical approach
is needed that yields core outcome measures minimizing
potential biases and that accommodates most of the inev-
itable variation in study design, recruitment and follow-
up.
The primary goal of a global database is to generate com-
parable and reliable estimates of antimalarial drug effi-
cacy, across a wide range of studies from different
geographical areas. The aim is to produce and disseminate
standardized estimates of efficacy that will be readily
accessible to researchers and policy makers alike (Figure
3). The initial focus will be to generate overall measures of
efficacy stratified by key confounding factors such as
patient age and parasitaemia. More complex correlations
with in vitro, pharmacokinetic and molecular markers of
drug resistance could be explored later.
The Solution
All efficacy studies begin with patients enrolled in a study
protocol and treated for malaria. Most studies end when
the patient meets the criteria for failure or the patient is
followed for some pre-determined duration without
meeting criteria for failure. Given variations in duration of
follow-up, survival analysis is generally regarded as the
most appropriate analytical approach [12,7,10]. If a
patient observation period ends prematurely and treat-
ment failure did not occur, then that patient is "censored"
at the time s/he was last observed.
The use of survival analysis offers the following important
advantages :
1) Data from patients with different follow-up periods can
be combined and efficacy estimates generated at differentMalaria Journal 2007, 6:119 http://www.biomedcentral.com/1475-2875/6/119
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time points. These can then be compared between studies
with different length of follow-up.
2) All available data contributes in the analysis, thus
increasing the precision of the derived estimates.
3) The approach avoids systematic biases introduced by
dropping patients from the analysis that do not complete
follow-up (per-protocol analysis) or classifying patients as
failures who do not represent true biological failures
(intention-to-treat analysis).
In survival data each patient is characterized by a period
of observation and whether or not treatment failure
occurred during this observation period (the "status").
This can be derived from four key parameters:
1) The last day of follow-up
2) The patient outcome on the last day of follow-up
3) The parasite species on the day of failure
4) The genotyping results (recrudescence, reinfection, no
result)
The outcomes for all patients on the last day of follow-up
need to be categorized into mutually exclusive groups that
cover all possible endpoints (Table 1). These can be
broadly divided into three groups.
1) Patients who complete the study and do not meet cri-
teria for treatment failure. For these patients, the last day
of follow-up is the full duration of the study period.
2) Patients who meet criteria for treatment failure; in this
case the last day of follow-up is the day when treatment
failure occurred.
The major goals of the analytical and methodological approach to collating data Figure 3
The major goals of the analytical and methodological approach to collating data.
x Accommodate the diversity in study designs and data collection methods 
x Minimise systematic bias 
x Maximise the use of the available data 
x Account for all patients enrolled in study
x Create a well-defined, transparent and reproducible method of analysis 
x Allow flexibility in case of changes in definitions of the therapeutic 
response
x Provide a resource that is easy to use and sustainable
Table 1: Key variables requested by the global efficacy database
Time and space variables# Baseline variables Primary outcome variables Secondary outcome variables *
Study Site Study identifier
Date of enrollment
Unique patient ID
Treatment
Parasite species
Age
Parasite density
Patient weight
Last day of follow-up
Outcome on last day of follow-up
Species on day of failure
Genotyping result on day of failure
Parasite clearance
Fever clearance
Change in haemoglobin
Gametocyte carriage
Adverse events
Variables in bold represent the key parameters necessary for deriving estimates of efficacy for each regimen.
* Additional variables that could be incorporated for analyses of secondary outcomes
# Study site details will be collated separately from the data at the individual patient level., and filed once for any study but linked to each individual 
patient record.
For more details see [13]Malaria Journal 2007, 6:119 http://www.biomedcentral.com/1475-2875/6/119
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3) Patients who neither complete the full follow-up
period nor meet the criteria for treatment failure (e.g. lost
to follow-up, withdrawal of consent, use of other antima-
larials, protocol violations, infection with other species
etc.). For these patients, the last day of follow is the day
when the patient was last observed.
Since the primary objective is to determine the prevalence
of parasite resistance, failure is defined as early treatment
failure during the first few days after the start of treatment
or the first reappearance or persistence of parasitaemia
during subsequent follow-up. These definitions are con-
sistent with the current WHO guidelines.
Condensing the patients' in vivo response into the four
simple parameters listed above, allows one to generate in
a transparent and flexible manner, the status of the patient
required for survival analysis. Table 2 shows an example
of a coding table which allows reviewers to appreciate
how various protocol violations were dealt with and thus
the shortcomings of the derived estimates. If additional
baseline data are available, one can then stratify the effi-
cacy estimates according to important baseline line con-
founding variables (Table 3).
The proposed system standardizes the process of data col-
lection in a robust and yet flexible manner, allowing an
analysis that accommodates the inevitable diversity of
study methodologies and collection methods. Impor-
tantly it still retains the ability to present alternative anal-
yses, such as proportions of failures on any particular day.
Whatever analytical method is used the process should be
transparent to analysts interpreting the findings. Such
transparency is now evident from the coding table (Table
2). This approach of using standardized terminology
greatly facilitates the ability to upload and cross check
individual patient study data to a global resource. Once
pooled estimates of efficacy can be readily generated and
compared across geographically and temporally disparate
studies.
Data can be gathered retrospectively from completed
studies but this may require recoding of the data to pro-
duce the key parameters outlined in Table 3 (for further
details see reference [13]. If the collection of these key
parameters are incorporated prospectively into studies,
then the process is simplified greatly.
The Outputs
The global database will initially focus on deriving six
standardized efficacy estimates: the cumulative incidence
of  Plasmodium falciparum recurrence (unadjusted and
adjusted by genotyping) up to day 28 and day 42 and the
cumulative risk of recurrence with Plasmodium vivax at day
28 and day 42. Subgroup analyses could be performed
selecting patients according to certain age and parasitae-
mic limits to minimize the confounding of immunity and
parasite biomass.
Although the risk of treatment failure is the main compo-
nent of the therapeutic response, other parameters of
interest can also be included, such as parasite and fever
clearance times, haematological recovery, gametocyte car-
riage, and drug safety and tolerability (Table 3). As data
collection methods become standardized (see below), it
will become feasible to link and present these data.
To demonstrate the utility of such a system data have been
collected from 82 studies with 162 treatment arms from
25 countries. In total individual records from 25,214
patients have already been pooled and the day 28 recur-
rence rates estimated (PCR adjusted and unadjusted). The
Table 2: Description of possible outcomes on the last day of 
follow-up for patients enrolled in clinical efficacy studies
Variable 
code
Description
Patients who complete the study
0 ACPR
1 ETF and Death
2 ETF with Severe Malaria
3 ETF with Danger Signs
4E T F  w i t h  P a r a s i t o l o gical Criteria (day 2 > day 0 or day 3 > 
25% day 0)
5 ETF with Clinical Criteria (documented fever and 
parasitaemia on day 3)
6 ETF not otherwise specified (for when details of why ETF 
classified not available)
7 LCF and Death
8 LCF with Severe Signs
9 LCF with Danger Signs
10 LCF with fever (either measured or subjective)
11 LPF
12 LPF/LCF Indistinguishable (for when details of why LCF/
LPF classified not available)
Patients who do not complete the study
13 Adverse event requiring change in therapy prior to 
completion of full dose
14 Protocol violation
15 Death not due to malaria
16 Lost to follow-up
17 Use of other antimalarials outside of study protocol in the 
absence of parasitaemia
18 Withdrawal of consent by patient prohibiting further 
follow-up
19 Investigator initiated withdrawal from further follow-up
20 Patient who does not complete follow-up for any other 
reason not listed above
21 Enrolment Violations
ACPR – Adequate Clinical and Parasitological Response; ETF – Early 
Treatment
Failure; LPF – Late Parasitological Failure; LCF – Late Clinical FailureMalaria Journal 2007, 6:119 http://www.biomedcentral.com/1475-2875/6/119
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latter are available online [13] along with an example of a
single study contribution and details on how the data
should be coded. It is important to emphasize that if data
are collected in this simplified mode at the outset, then
the cumulative incidence of failure for each study can be
generated easily using survival analysis, whilst retaining
the ability to peruse other statistical outputs.
Potential for future developments
The goal of a global database is to characterize temporal
and geographical trends in antimalarial efficacy, allowing
information-based decision making among health policy
developers and implementers. Retrospective analysis of
the demise of old drugs could potentially provide useful
information on how a similar fate might be avoided when
deploying new treatments. Ultimately, the strength of an
international resource lies in its ability to collate and
report rapidly the current data on antimalarial efficacy.
This will ensure that the international community has the
best opportunity to detect and react to the earliest warn-
ings of failing drug regimens. The additional benefit of
documenting what is currently known is that it becomes
apparent where important gaps in the data exist, thus
helping to prioritize clinical and parasitological studies of
antimalarial efficacy in these areas.
Another important component of the World Antimalarial
Resistance Network will be the development of additional
resources to increase local capacity to conduct and inter-
pret clinical trials. In this respect an open-access software
program will be developed to provide a universal data-
base system ready for sites to implement. This free soft-
ware would provide a much needed service to clinical
investigators conducting antimalarial efficacy trials in
malaria endemic countries. At the same time, the data
would be collected in a format that could easily be
uploaded to the global database, at the discretion of the
local study team. The system would also promote adher-
ence to standardized protocols and facilitate the collec-
tion of the most critical variables for basic efficacy and
safety measurements.
As the data from the other global databases proposed in
this edition of the journal accrue, the opportunity will
arise to cross-link molecular, in vitro susceptibility assays
and pharmacokinetic parameters with the clinical data.
This can be done both at the population (in time and
place) or individual level. Such merging will allow the
investigation and validation of surrogate markers of clini-
cal efficacy. The power of a comprehensive data collection
would allow a multivariate analysis to identify parame-
Table 3: The derivation of the patients status on the last day of follow, which is required for survival analysis
Key Variable Status
Species at 
Enrollment *
Outcome † Species at Failure * PCR Correction 
**
PF Unadjusted by 
genotyping φ
PF Recrudescence 
φ
PV Recurrence φ
1–5 0 N/A N/A 0 0 0
Any 1–6 1 N/A 1 1 0
Any 1–6 2 N/A 0 0 1
1  o r  3  o r  4 7 – 1 2 1  o r  4 1100
1  o r  3  o r  4 7 – 1 2 1  o r  4 2110
1 or 3 or 4 7–12 1 or 4 3 1 § 0
1  o r  3  o r  4 7 – 1 2 31101
1  o r  3  o r  4 7 – 1 2 32111
1 or 3 or 4 7–12 3 3 1 § 1
1 or 3 or 4 7–12 2 or 5 N/A 0 0 1
1 or 3 or 4 7–12 6 N/A 0 0 0
2 or 5 7–12 1 or 4 N/A 1 - 0
2 or 5 7–12 3 N/A 1 - 1
2 or 5 7–12 2 or 5 N/A 0 - 1
2 or 5 7–12 6 N/A 0 - 0
1–5 13–20 N/A N/A 0 0 0
1–5 21 N/A N/A - - -
* 1 = Pf monoinfection; 2 = Pv monoinfection; 3 = Pf + Pv mixed; 4 = Pf mixed, but Pv not present; 5 = Pv mixed, but Pf not present, 6 = Other 
Species not Pf or Pv
** 1 = Reinfection, 2 = Recrudescence, 3 = Unavailable/Uninterpretable; N/A = Not applicable
† See Table 2 φ 0 = Not a failure; 1 = Failure
§As yet there is no consensus as to how to deal with indeterminate PCR results, although strategies to deal with these are being developed. 
Currently these are excluded from the PCR corrected analysis.Malaria Journal 2007, 6:119 http://www.biomedcentral.com/1475-2875/6/119
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ters, other than parasite resistance, associated with the
therapeutic outcomes. This information could then be
used to rationalize public health strategies (e.g. optimiz-
ing dosing recommendations and identification of groups
of patients at particular risk).
Challenges ahead
There are numerous challenges to interpret the data that
have already been gathered, and to develop acceptable
and reliable methodologies that will improve study
design and data collection and analysis in the future. The
first step toward these goals is to ensure that research
groups, policymakers, governing bodies and funding
agencies perceive tangible benefits that can be accrued
from sharing both data and methodologies. These bene-
fits need to be balanced by the perceived risks to owner-
ship and privacy when releasing individual patient data to
a third party. Transparent protocols need to be developed
that comply with international ethical standards, protect
intellectual property rights, and ensure that patient data
remain confidential.
Five key variables are required to derive efficacy estimates
for each treatment (Table 3). Subgroup analyses by and
large are fairly standard and amenable to strict definitions.
The major exception to this is the genotype of the recur-
rent infection (recrudescent, reinfection or unavailable/
uninterpretable). The methodology used to derive these
three categories varies markedly between research units,
with some using one marker and others a multitude of
markers [8]. In areas of high transmission, the interpreta-
tion of these parameters in polyclonal infections is at best
challenging and at worst impossible. Debate on how to
deal with these issues is gathering momentum and in the
coming year, it is hoped that consensus and recommenda-
tions for standard approaches will be agreed upon. In the
meantime there is no option but to rely on local practices.
However since the genotype parameter remains a crucial
component for estimating true recrudescence, details of
these methods and protocol design must accompany all
contributions to the global database, so that the validity of
the data can be assessed.
Where drug efficacy surveillance systems are being devel-
oped the benefits of adopting established methodologies
and analytical approaches are compelling. However it is
often difficult to change a system that is already in place
and appears adapted to local needs. The challenge is to
ensure that the proposed changes in the coding of data are
simple and easily incorporated into established practices.
Importantly the uniform collection of the key variables
advocated in this paper will circumvent the inevitable var-
iations in protocol design and execution, which reflect
local requirements and capacities. From the feedback of
the participants in a pilot project, it appears that this is so,
and that, importantly, the process of cleaning, validating
and analyzing data is greatly improved. This is currently
an evolving system and, therefore, there are likely to be
problems that need to be resolved and areas that need fur-
ther clarification. Feedback from those involved in con-
ducting efficacy studies is welcomed and can be registered
as a readers comment on this article.
Conclusion
In the last ten years the emergence of multidrug resistant
strains of plasmodia raised the spectre of untreatable
malaria for poorly resourced communities. The develop-
ment of ACTs has brought the hope of not only rescuing
some compromised antimalarial drugs, but also delaying
the emergence and spread of new resistant strains. In addi-
tion improved funding has paved the way for the discov-
ery of novel antimalarial compounds, some of which
should become available in the next two to ten years.
Although the next ten years look much brighter for
malaria treatment programmes, it would be a disaster if
that led to complacency. Plasmodia have proved efficient
at evolving resistance to novel agents and this is likely to
continue. Hence it is vital that prospective monitoring of
antimalarial drug efficacy remains an international prior-
ity, with estimates of clinical efficacy and in vitro suscepti-
bility testing central to detecting early warning signals of
resistance to ACTs. Furthermore developing a global
resistance database to track clinical efficacy will help
rationalize treatment practices, ensure ongoing surveil-
lance, and identify factors most conducive to maintaining
parasite susceptibility to available treatment regimens.
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